Skip to main content
NewslettersWatchlist

Bristol-Myers Squibb Company(BMY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low57.47
Day High58.38
Open:58.16
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Is Bristol Myers Squibb Stock a Buy?
Motley Fool
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Barchart
Stocks Settle Sharply Lower on the Outlook for Slower Fed Rate Cuts
Motley Fool
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
Motley Fool
2 Beaten-Down Dividend Stocks to Buy and Hold
Barchart
Stock Index Futures Muted as Trump Rally Pauses, U.S. Inflation Data and Fed Speak Awaited
Barchart
What's Behind the Insider Buying on This High-Yield Stock?
Barchart
Stocks Settle Mostly Higher on President-Elect Trump’s Pro-Growth Promises
Barchart
Stocks Rally on Optimism in President-Elect Trump’s Policies
Barchart
S&P 500 and Dow Jones Industrials at Record Highs as the Post-Election Rally Continues
MarketBeat
MarketBeat Week in Review – 11/4 - 11/8
Barchart
1 Penny Stock to Grab Now for 183% Upside Potential
MarketBeat
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
Barchart
Option Volatility And Earnings Report For November 4 - 8
Motley Fool
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
Barchart
1 Healthcare REIT to Snag Now for 5% Yield
Barchart
2 Promising Growth Stocks to Buy and Hold for a Decade or Longer
Barchart
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?
Motley Fool
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Motley Fool
2 Passive-Income Stocks to Load Up On in October
Motley Fool
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now

Profile

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.